Qing-Luo-Yin Eased Adjuvant-Induced Arthritis by Inhibiting SIRT1-Controlled Visfatin Production in White Adipose Tissues
Dan-Dan Wang,Meng-Ke Song,Qin Yin,Wen-Gang Chen,Opeyemi Joshua Olatunji,Kui Yang,Jian Zuo
DOI: https://doi.org/10.2147/jir.s474329
IF: 4.5
2024-09-25
Journal of Inflammation Research
Abstract:Dan-Dan Wang, 1, 2, &ast Meng-Ke Song, 1, 3, &ast Qin Yin, 1, 2 Wen-Gang Chen, 2 Opeyemi Joshua Olatunji, 4 Kui Yang, 3 Jian Zuo 1, 3, 5 1 Xin'an Medicine Research Center, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital), Wuhu, 241000, People's Republic of China; 2 Department of Pharmacy, the Second Affiliated Hospital of Wannan Medical College, Wuhu, 241000, People's Republic of China; 3 Research Center of Integration of Traditional Chinese and Western Medicine, Wannan Medical College, Wuhu, 241000, People's Republic of China; 4 African Genome Center, Mohammed VI Polytechnic University, Ben Guerir, 43150, Morocco; 5 Anhui Province Key Laboratory of Non-Coding RNA Basic and Clinical Transformation, Wannan Medical College, Wuhu, 241000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Kui Yang; Jian Zuo, Email ; Background: Nicotinamide adenine dinucleotide (NAD)-dependent deacetylase SIRT1 regulates both metabolism and immune functions. This study investigated if SIRT1 inhibitory property of herbal formula Qing-Luo-Yin (QLY) contributed to its anti-rheumatic effects. Methods: Adjuvant-induced arthritis (AIA) rats were treated by QLY and nicotinamide mononucleotide (NMN, a biosynthesis precursor of NAD) for 38 days. After sacrifice, blood, paws, liver and white adipose tissues (WAT) were collected. Pre-adipocytes were cultured by the rats' serum. The medium was used for monocytes culture. Some pre-adipocytes were treated by QLY-derived SIRT1 inhibitors. SIRT1 was silenced or overexpressed beforehand. The samples were subjected to kits-based quantification, polymerase-chain reaction, western-blot, immunofluorescence, and histology experiments. Results: AIA rats experienced significant fat loss in liver and WAT. Expression of many SIRT1-related signals like PPARγ, PGC-1α, HSL, ATGL and CPT-1A were altered. QLY attenuated all these abnormalities and joint injuries. By pan-acetylation up-regulation, visfatin was obviously reduced in QLY-treated AIA rats' blood (from 191.8 to 127.0 pg/mL). NMN sustained SIRT1 activation by replenishing NAD, and weakened these effects. QLY-containing serum and the related compounds showed similar impacts on pre-adipocytes, resembling the changes in QLY-treated AIA rats' WAT. These treatments suppressed AIA serum-induced visfatin secretion (from 49.3 to 36.1 and 30.7 pg/mL). This effect was impaired by SIRT1 overexpression. The medium from the compounds-treated pre-adipocytes impaired NF-κB activation in AIA serum-cultured monocytes. Conclusion: Besides fat depletion, SIRT1 up-regulation in rheumatic subjects' WAT promotes visfatin production, and exacerbates inflammation. SIRT1 inhibition in WAT is an anti-rheumatic way of QLY independent of immune regulation. Keywords: visfatin, PPARγ, rheumatoid arthritis, Traditional Chinese Medicine, adipocyte Rheumatoid arthritis (RA) is characterized by an initial state of autoimmune reactions, which eventually leads to persistent inflammation and tissue degradation in joints. 1 RA progression is predominantly driven by T cells. Their hyper-activation culminates in disruption of cytokines network. Increase of inflammatory cytokines like IL-1, IL-6, and IL-17 directly accounts for most of RA-related manifestations. 2 It should be aware that monocytes/macrophages are key sources of these factors too, which contribute to RA pathology in multiple aspects. They activate T lymphocytes and many effector cells, differentiate toward osteoblasts, and drive synovial angiogenesis. 3–6 In brief, macrophages and the precursors (monocytes) show inflammatory phenotype in RA. 5–7 Their functional shift is an indicator of RA progression. 8 Any approaches that can affect their polarization would possibly benefit RA patients. Conventional anti-RA therapies typically include non-steroidal anti-inflammatory drugs, glucocorticoids and disease-modifying antirheumatic drugs. Many of them exhibit potentials in regulating monocytes/macrophages. 4,9 Benefited from the significant advance in RA pathology, novel biological agents are applied in treating RA, represented by TNF-α neutralizing antibodies and selective JAK inhibitors, which are designed to preferentially abrogate pathological differentiation and functions of lymphocytes. 10 More endeavors should be devoted to develop monocytes/macrophages-targeting drugs. Beyond immune mediators, energy metabolism status represents another critical determinant for functions -Abstract Truncated-
immunology